REFERENCES
- Oliver S. E., May M. T., Gunnell D. International trends in prostate cancer mortality in the “PSA era.”. Int. J. Cancer 2001; 92: 893–898, [INFOTRIEVE], [CSA]
- Hsing A. W., Tsao L., Devesa S. S. International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer. 2000; 85: 60–67, [INFOTRIEVE], [CROSSREF], [CSA]
- Narod S. Genetic epidemiology of prostate cancer. Biochim. Biophys. Acta 1999; 1423(1)F1–13, [INFOTRIEVE], [CSA]
- Woutersen R. A., Appel M. J., van Garderen-Hoetmer A., Wijnands M. V. Dietary fat and carcinogenesis. Mutat. Res. 1999; 443(1–2)111–127, [INFOTRIEVE], [CSA]
- Siddiqui M. K., Srivastava S., Mehrotra P. K. Environmental exposure to lead as a risk for prostate cancer. Biomed. Environ. Sci. 2002; 15(4)298–305, [INFOTRIEVE], [CSA]
- Scher H. I. Prostate carcinoma: defining therapeutic objectives and improving overall outcomes. Cancer 2003; 97(3 Suppl.)758–771, [INFOTRIEVE], [CROSSREF], [CSA]
- Baijal-Gupta M., Clarke M. W., Finkelman M. A., McLachlin C. M., Han V. K. Prostatic secretory protein (PSP94) expression in human female reproductive tissues, breast and in endometrial cancer cell lines. J. Endocrinol. 2000; 165(2)425–433, [INFOTRIEVE], [CROSSREF], [CSA]
- Weiber H., Andersson C., Murne A., Rannevik G., Lindstrom H. L., et al. b-Microseminoprotein is not a prostate-specific protein (Its identification in mucous glands and secretions). Amer. J. Path. 1990; 137(3)593–603, [INFOTRIEVE], [CSA]
- Lilja H., Abrahamsson P. A. Three predominant proteins secreted by the human prostate gland. Prostate. 1988; 12: 29–38, [INFOTRIEVE], [CSA]
- Fernlund P., Granberg L. B., Larsson I. Cloning of b-microseminoprotein of the rat: a rapidly evolving mucosal surface protein. Arch. Biochem. Biophys. 1996; 334(1)73–82, [INFOTRIEVE], [CROSSREF], [CSA]
- Xuan J. W., Wu D., Guo Y., Garde S. V., Shum D., et al. Molecular cloning and gene expression analysis of PSP94 (prostatic secretory protein of 94 amino acids) in primates. DNA Cell. Biol. 1997; 16: 627–638, [CSA]
- Lazure C., Villemure M., Gauthier D., Naude R. J., Mbikay M. Characterization of ostrich (Struthio camelus) b-microseminoprotein (MSP): identification of homologous sequences in EST databases and analysis of their evolution during speciation. Protein Sci. 2001; 10: 2207–2218, [INFOTRIEVE], [CROSSREF], [CSA]
- Brar A., Mbikay M., Sirois F., Fournier S., Seidah N. G., et al. Localization of the human prostatic secretory protein PSP94 and its mRNA in the epithelial cells of the prostate. J. Androl. 1988; 9(4)253–260, [INFOTRIEVE], [CSA]
- Hurkadli K. S., Lokeshwar B., Sheth A. R., Block N. L. Detection of prostatic-inhibin-like peptide in the cytoplasm of LNCaP cells, a human prostatic adenocarcinoma cell line. Prostate 1994; 24(6)285–290, [INFOTRIEVE], [CSA]
- Phadke M., Vijayalakshmi S., Sheth A. R. Evidence for the presence of specific receptors for inhibin in human prostate. Ind. J. Exp. Biol. 1982; 20(5)419–420, [CSA]
- Zhang P. J., Driscoll D. L., Lee H. K., Nolan C., Velagapudi S. R. Decreased immunoexpression of prostate inhibin peptide in prostatic carcinoma: a study with monoclonal antibody. Hum. Pathol. 1999; 30(2)168–172, [INFOTRIEVE], [CROSSREF], [CSA]
- Tsurusaki T., Koji T., Sakai H., Kanetake H., Nakane P. K., et al. Cellular expression of beta-microseminoprotein (beta-MSP) mRNA and its protein in untreated prostate cancer. Prostate 1998; 35(2)109–116, [INFOTRIEVE], [CROSSREF], [CSA]
- Wu D., Guo Y., Chambers A. F., Izawa J. I., Chin J. L., et al. Serum bound forms of PSP94 (prostate secretory protein of 94 amino acids) in prostate cancer patients. J. Cell. Biochem. 1999; 76(1)71–83, [INFOTRIEVE], [CROSSREF], [CSA]
- von d er, Kammerm H., Jurincic-Winkler C., Horlbeck R., Klippel K. F., Pixberg H. U., et al. The potential use of prostatic secretory protein of 94 amino acid residues (PSP94) as a serum marker for prostatic tumor. Urol. Res. 1993; 21(3)227–233, [CROSSREF], [CSA]
- Teni T. R., Bandivdekar A. H., Sheth A. R., Sheth N. A. Prostatic inhibin-like peptide quantified in urine of prostatic cancer patients by enzyme-linked immunosorbent assay. Clin. Chem. 1989; 35(7)1376–1379, [INFOTRIEVE], [CSA]
- Tremblay J., Frenette G., Tremblay R. R., Dupont A., Thabet M., et al. Excretion of three major prostatic secretory proteins in the urine of normal men and patients with benign prostatic hypertrophy or prostate cancer. Prostate 1987; 10(3)235–243, [INFOTRIEVE], [CSA]
- Lokeshwar B. L., Hurkadli K. S., Sheth A. R., Block N. L. Human prostatic inhibin suppresses tumor growth and inhibits clonogenic survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor. Cancer Res. 1993; 53: 4855–4859, [INFOTRIEVE], [CSA]
- Garde S. V., Sheth A. R., Porter A. T., Pienta K. J. Effect of prostatic inhibin peptide (PIP) on prostate cancer growth in vitro and in vivo. Prostate 1993; 22: 225–233, [INFOTRIEVE], [CSA]
- Garde S. V., Basrur V. S., Li L., Finkelman M. A., Krishan A., et al. Prostate Secretory Protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. Prostate 1999; 38: 118–125, [INFOTRIEVE], [CROSSREF], [CSA]
- Shukeir N., Arakelian A., Kadhim S., Garde S., Rabbani S. A. Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngeneic in vivomodel of prostate cancer. Cancer Res. 2003; 63(9)2072–2078, [INFOTRIEVE], [CSA]
- Strathdee C. A., McLeod M. R., Hall J. R. Efficient control of tetracycline-responsive gene expression from an autoregulated bi-directional expression vector. Gene 1999; 229 1–2: 21–29, [INFOTRIEVE], [CROSSREF], [CSA]
- Pollard M., Luckert P. H. Transplantable metastasizing prostate adenocarcinomas in rats. J. Natl. Canc. Inst. 1975; 54(3)643–649, [CSA]
- Koutsilieris M. PA-III rat prostate adenocarcinoma cells (Review). In vivo 1992; 6: 199–204, [INFOTRIEVE], [CSA]
- Xuan J. W., Kwong J., Chan F. L., Ricci M., Imasato Y., et al. cDNA, genomic cloning, and gene expression analysis of mouse PSP94 (prostatic secretory protein of 94 amino acids). DNA Cell Biol. 1999; 18(1)11–26, [INFOTRIEVE], [CROSSREF], [CSA]
- Bharti A. C., Takada Y., Shishodia S., Aggarwal B. B. Evidence that receptor activator of nuclear factor (NF)-kappaB ligand can suppress cell proliferation and induce apoptosis through activation of a NF-kappaB-independent and TRAF6-dependent mechanism. J. Biol. Chem. 2004; 279(7)6065–6076, [INFOTRIEVE], [CROSSREF], [CSA]
- Schaaf M. J., Cidlowski J. A. Molecular mechanisms of glucocorticoid action and resistance. J. Ster. Biochem. Mol. Biol. 2002; 83 1–5: 37–48, [CROSSREF], [CSA]
- McArdle C. A., Franklin J., Green L., Hislop J. N. The gonadotrophin-releasing hormone receptor: signaling, cycling and desensitization. Arch. Physiol. Biochem. 2002; 110 1–2: 113–122, [INFOTRIEVE], [CROSSREF], [CSA]